• Study on the presence of antipolymer antibodies in a group of Dutch women with a silicone breast implant

      Jong WH de; Goldhoorn CA; Kallewaard M; Spiekstra Sw; Hoedt E den; Geertsma RE; Loveren H van; Schouten JSAG; LPI; LGM; CZE; VTV; AZU (Academisch Ziekenhuis Utrecht AZU, 1999-10-31)
      The purpose of the study described in this report was to determine whether there exists a population of Dutch women with high prevalence of antipolymer antibodies (APA) and severe complaints, and exposure to a SBI. As the antigen specific nature of the antipolymer antibody has not yet been established, we refer to the term polymer binding immunoglobulins. The study population was selected from a voluntary registry of SBI recipients of a Dutch consumers (Consumentenbond, The Hague, The Netherlands) organisation. The final selection was based on self reported complaints in a questionnaire which was used to determine the complaints at the time of the study. A total of 42 SBI recipients was included in the study, clinically examined and blood samples were obtained. Only in a few SBI recipients an increase in the level of polymer binding immunoglobulins was detected. Also in a few blood samples of non SBI recipients, included for control on the performance of the APA assay, an increase in the level of polymer binding immunoglobulins was demonstrated. As the mean duration of the SBI implant was 17 years it can be concluded that exposure to silicones does not lead to the induction of polymer binding immunoglobulins. The study population of SBI recipients was categorized in severity subgroups based on the functional capacity, and the physicians global assessment of pain and disease activity. Most (34 of 42) SBI recipients belonged to the limited severity subgroup on a increasing scale of limited, mild, moderate and advanced. Conclusively, our selection method failed to include a large proportion of SBI recipients which could be categorized in the moderate or advanced severity subgroups. In this respect our study population is not comparable to the severity subgroups of SBI recipients or severe fibromyalgia patients reported to have a high prevalence of antipolymer antibodies.